These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 14637073)

  • 1. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
    Morelli M
    Exp Neurol; 2003 Nov; 184(1):20-3. PubMed ID: 14637073
    [No Abstract]   [Full Text] [Related]  

  • 2. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
    Boia R; Ambrósio AF; Santiago AR
    Ophthalmic Res; 2016; 55(4):212-8. PubMed ID: 26959995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
    Schwarzschild MA; Chen JF; Ascherio A
    Neurology; 2002 Apr; 58(8):1154-60. PubMed ID: 11971080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
    Kelsey JE; Langelier NA; Oriel BS; Reedy C
    Psychopharmacology (Berl); 2009 Jan; 201(4):529-39. PubMed ID: 18791705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
    Mori A
    Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
    Petzer JP; Petzer A
    Curr Med Chem; 2015; 22(8):975-88. PubMed ID: 25544641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Weiss SM; Benwell K; Cliffe IA; Gillespie RJ; Knight AR; Lerpiniere J; Misra A; Pratt RM; Revell D; Upton R; Dourish CT
    Neurology; 2003 Dec; 61(11 Suppl 6):S101-6. PubMed ID: 14663021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
    Bové J; Serrats J; Mengod G; Cortés R; Tolosa E; Marin C
    Exp Brain Res; 2005 Sep; 165(3):362-74. PubMed ID: 15968457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
    Ongini E
    Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
    [No Abstract]   [Full Text] [Related]  

  • 14. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives.
    Matsumura N; Aoyama K
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic progress--review XX. Drug treatment of Parkinson's disease.
    Pall HS; Williams AC; Ramsden DB
    J Clin Hosp Pharm; 1986 Aug; 11(4):229-36. PubMed ID: 3531240
    [No Abstract]   [Full Text] [Related]  

  • 17. A
    Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
    Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeine as a neuroprotective adenosine receptor antagonist.
    Dall'Igna OP; Souza DO; Lara DR
    Ann Pharmacother; 2004 Apr; 38(4):717-8. PubMed ID: 14982979
    [No Abstract]   [Full Text] [Related]  

  • 20. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
    Reichmann H
    Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.